caa a22 4500 445807970 CHVBK 20180317145202.0 cr unu---uuuuu 170323e20110901xx s 000 0 eng 10.1007/s00415-011-5988-y doi (NATIONALLICENCE)springer-10.1007/s00415-011-5988-y Three year follow up of levodopa plus carbidopa treatment in a prevalent cohort of patients with Parkinson's disease in Hai, Tanzania [Elektronische Daten] [Catherine Dotchin, Ahmed Jusabani, Richard Walker] It was previously thought that the prevalence of Parkinson's disease (PD) in developing countries, and in particular sub-Saharan Africa (SSA), was lower than the rest of the world. The Hai PD prevalence project [1] diagnosed 32 patients (the majority previously undiagnosed and untreated) with PD from a population of 161,000, giving age standardised prevalence rates of 64 (men) and 20 (women)/100,000, respectively. Subsequently, drug treatment has been commenced for all surviving patients with annual follow up. The aim of the study was to document response to treatment, development of side effects, progression of disease and feasibility and sustainability of supplying medication to patients in rural Tanzania. Eleven patients died before the start of medication, and a further four during follow up. One patient moved away from the study area. At the end of 3years of treatment, 16 patients were surviving. Only one stopped medication due to side effects (dyskinesia). At 3years, 9/16 experienced wearing off and a further three had dyskinesias. Non motor symptoms were a problem at initial assessment [2] and continued to be a problem for many of the patients. We have shown that it is possible to find, treat and follow up patients with PD in a rural sub-Saharan African setting. Availability of affordable medication locally is a major issue. Acknowledging that movement disorders and neurological diseases in general are an issue in this setting is important to drive education and training, and for allocation of funding from health care providers in SSA. Springer-Verlag, 2011 Parkinson's disease nationallicence Mortality nationallicence Sub-Saharan Africa nationallicence Levodopa nationallicence Dotchin Catherine Wolfson Research Centre, Institute for Ageing and Health, Newcastle University, Campus for Ageing and Vitality, NE4 5PL, Newcastle upon Tyne, UK aut Jusabani Ahmed Department of Radiology, Kilimanjaro Christian Medical Centre, 3010, Moshi, Tanzania aut Walker Richard Department of Medicine, Northumbria Healthcare NHS Foundation Trust, North Tyneside General Hospital, Rake Lane, North Shields, NE29 8NH, Tyne and Wear, UK aut Journal of Neurology Springer-Verlag 258/9(2011-09-01), 1649-1656 0340-5354 258:9<1649 2011 258 415 https://doi.org/10.1007/s00415-011-5988-y text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00415-011-5988-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Dotchin Catherine Wolfson Research Centre, Institute for Ageing and Health, Newcastle University, Campus for Ageing and Vitality, NE4 5PL, Newcastle upon Tyne, UK aut NATIONALLICENCE 700 1- Jusabani Ahmed Department of Radiology, Kilimanjaro Christian Medical Centre, 3010, Moshi, Tanzania aut NATIONALLICENCE 700 1- Walker Richard Department of Medicine, Northumbria Healthcare NHS Foundation Trust, North Tyneside General Hospital, Rake Lane, North Shields, NE29 8NH, Tyne and Wear, UK aut NATIONALLICENCE 773 0- Journal of Neurology Springer-Verlag 258/9(2011-09-01), 1649-1656 0340-5354 258:9<1649 2011 258 415 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer